Sjögren's Syndrome Market to Witness Sustained Growth During the Forecast Period (2026-2036) Due to the Development of Targeted Immunotherapies, FcRn Inhibitors, TYK2 Inhibitors, and Cell Therapies | DelveInsight

Summary

Market analysis report highlights growth potential in Sjögren's syndrome treatment landscape with emerging targeted immunotherapies including candidates from Amgen, Johnson & Johnson, and Vor Biopharma moving beyond traditional symptomatic management.